{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:50:45Z","timestamp":1765882245297,"version":"3.48.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This meta-analysis aimed to evaluate the efficacy and safety profiles of insulin efsitora in the treatment of type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive systematic search across PubMed, the Cochrane Library, and Embase from database inception through September 11, 2025. The study included randomized controlled trials (RCTs) that directly compared insulin efsitora with once daily basal insulin in T2D patients. Primary outcomes assessed were changes in hemoglobin A1c (HbA1c) and body weight. Methodological quality and risk of bias were evaluated using the Cochrane Quality Assessment Tool. Data synthesis was performed using random-effects models to calculate risk ratios (RR) and mean differences (MD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The meta-analysis incorporated six RCTs involving 4116 participants. Our findings revealed no statistically significant difference in HbA1c reduction between insulin efsitora and once daily basal insulins (MD: -0.04%; 95% CI: -0.10% to 0.02%; p = 0.78). Other outcomes, including change in body weight, body mass index changes, proportion of patients achieving HbA1c &amp;lt; 7%, change in fasting plasma glucose, and various hypoglycemia events (level 1, level 2, and level 3), as well as adverse events and serious adverse events, showed comparable results between the two treatments. Notably, insulin efsitora demonstrated superior performance in total daily insulin dose and time in range (70-180 mg\/dL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Insulin efsitora demonstrates comparable efficacy and safety to once daily basal insulins in the management of T2D. However, given the limited number of RCTs available in the current evidence base, further large-scale clinical trials are warranted to validate these findings and establish more definitive conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1608458","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:46:38Z","timestamp":1765881998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of insulin efsitora in type 2 diabetes: a meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3760\/cma.j.cn115791-20210221-00095","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China","volume":"13","year":"2020","journal-title":"Chin J Diabetes Mellitus."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14956","article-title":"Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes","volume":"25","author":"Heise","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2396","article-title":"Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: A phase 2 randomized control trial","volume":"46","author":"Bue-Valleskey","year":"2023","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00388-6","article-title":"Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study","volume":"11","author":"Frias","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403953","article-title":"Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.12.013","article-title":"Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis","volume":"31","author":"Dutta","year":"2025","journal-title":"Endocr Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000723","DOI":"10.1136\/bmjdrc-2019-000723","article-title":"Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis","volume":"7","author":"Stuckey","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/00325481.2024.2410694","article-title":"Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes","volume":"136","author":"Morales","year":"2024","journal-title":"Postgrad Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"Higgins","year":"2024"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502796","article-title":"Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01044-X","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Philis-Tsimikas","year":"2025","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01069-4","article-title":"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial","volume":"405","author":"Blevins","year":"2025","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and hbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0251","article-title":"Time in range is associated with carotid intima-media thickness in type 2 diabetes","volume":"22","author":"Lu","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1987","article-title":"Intermediate diabetes outcomes in patients managed by physicians, nurse practitioners, or physician assistants: A cohort study","volume":"169","author":"Jackson","year":"2018","journal-title":"Ann Intern Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.amjmed.2017.08.026","article-title":"Nurse practitioners, physician assistants, and physicians are comparable in managing the first five years of diabetes","volume":"131","author":"Yang","year":"2018","journal-title":"Am J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000001065","article-title":"Icodec ONWARDS: A review of the first once-weekly diabetes treatment for nurse practitioners and physician assistants","volume":"37","author":"Kruger","year":"2025","journal-title":"J Am Assoc Nurse Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2877","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: A phase 2 randomized controlled trial","volume":"44","author":"Bajaj","year":"2021","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-weekly insulin for type 2 diabetes without previous insulin treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2878","article-title":"A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100","volume":"44","author":"Lingvay","year":"2021","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00520-2","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial","volume":"401","author":"Mathieu","year":"2023","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-024-01431-5","article-title":"Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis","volume":"23","author":"Zuhair","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01652-0","article-title":"Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin","volume":"15","author":"Gelsey","year":"2024","journal-title":"Diabetes Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0164","article-title":"Missed and mistimed insulin doses in people with diabetes: A systematic literature review","volume":"23","author":"Robinson","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-57","article-title":"The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ","volume":"5","author":"Bradley","year":"2007","journal-title":"Health Qual Life Outcomes."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00093-1","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial","volume":"11","author":"Philis-Tsimikas","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1288","article-title":"Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): A randomized trial","volume":"176","author":"Bajaj","year":"2023","journal-title":"Ann Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06158-9","article-title":"Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes","volume":"67","author":"Trevisan","year":"2024","journal-title":"Diabetologia."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0712","article-title":"Once-weekly insulin: A breakthrough in diabetes management or an unresolved challenge","volume":"86","author":"Ahmed","year":"2025","journal-title":"Br J Hosp Med (Lond)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing clinical inertia in type 2 diabetes mellitus: A review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e001194","DOI":"10.1136\/bmjdrc-2020-001194","article-title":"Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen","volume":"8","author":"Heller","year":"2020","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1608458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:46:42Z","timestamp":1765882002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1608458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":44,"alternative-id":["10.3389\/fendo.2025.1608458"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1608458","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"article-number":"1608458"}}